Shilpa Medicare Ltd (Shilpa Medicare) develops, manufactures, and markets a wide range of generic pharmaceutical products. The company is involved in producing and exporting active pharmaceutical ingredients (APIs), formulations, new drug delivery systems, peptides, specialty chemicals, and intermediates. Shilpa Medicare offers both oncology and non-oncology APIs, including anastrozole, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulfan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide monohydrate, dasatinib, decitabine, erlotinib HCL, fingolimod hydrochloride, gemcitabine HCL, imatinib mesylate, irinotecan HCL trihydrate, lenalidomide, letrozole, melphalan HCL, nifedipine, oxaliplatin, pemetrexed disodium hemipentahydrate, sunitinib malate, temozolomide, thalidomide, and zoledronic acid.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Shilpa Medicare places significant emphasis on research and development (R&D) to maintain its competitive edge in the pharmaceutical industry. Strategic collaborations with global partners strengthen the innovation pipeline, and ongoing investments in biosimilars and new biological entities reflect a long-term, future-ready strategy. R&D capabilities are supported by multiple specialized units: Raichur (niche small/large molecules and specialty biopolymers), Bengaluru (advanced analytical development), Hyderabad (API and formulation development), and Ahmedabad (FTF Pharma R&D), along with dedicated entities for advanced process technologies (Sravathi) and biologics development (Shilpa Biologicals). The R&D team is instrumental in developing a diverse portfolio of niche products aimed at various global markets, including the US, Canada, Japan, and the European Union. The company’s R&D activities have led to notable achievements, including 196 DMF filings, 213 patent filings, and 500 regulatory filings for formulations. In FY2025, the company invested INR485.7 million in its R&D activities, which grew by 56.2% YoY.